Basics |
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology.
|
IPO Date: |
October 7, 2015 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$122.36M |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$0.35 | 3.17%
|
Avg Daily Range (30 D): |
$0.04 | 3.26%
|
Avg Daily Range (90 D): |
$0.06 | 3.07%
|
Institutional Daily Volume |
Avg Daily Volume: |
.67M |
Avg Daily Volume (30 D): |
.86M |
Avg Daily Volume (90 D): |
.79M |
Trade Size |
Avg Trade Size (Sh.): |
156 |
Avg Trade Size (Sh.) (30 D): |
173 |
Avg Trade Size (Sh.) (90 D): |
150 |
Institutional Trades |
Total Inst.Trades: |
1,171 |
Avg Inst. Trade: |
$1.56M |
Avg Inst. Trade (30 D): |
$1.65M |
Avg Inst. Trade (90 D): |
$1.08M |
Avg Inst. Trade Volume: |
.13M |
Avg Inst. Trades (Per Day): |
1 |
Market Closing Trades |
Avg Closing Trade: |
$1.48M |
Avg Closing Trade (30 D): |
$2.52M |
Avg Closing Trade (90 D): |
$2.06M |
Avg Closing Volume: |
127.61K |
|
|
|
|
Financials |
|
TTM |
Q4 2024 |
FY 2024 |
Basic EPS
|
$-1.71
|
$-1.21
|
$-1.71
|
Diluted EPS
|
$-1.71
|
$-1.21
|
$-1.71
|
Revenue
|
$ 18.72M
|
$ 9.21M
|
$ 18.72M
|
Gross Profit
|
$ 15.93M
|
$ 8.51M
|
$ 15.93M
|
Net Income / Loss
|
$ -132.07M
|
$ -96.55M
|
$ -132.07M
|
Operating Income / Loss
|
$ -141.93M
|
$ -99.68M
|
$ -141.93M
|
Cost of Revenue
|
$ 2.79M
|
$ .71M
|
$ 2.79M
|
Net Cash Flow
|
$ -15.31M
|
$ -23.08M
|
$ -15.31M
|
PE Ratio
|
|
|
|
|